医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

Award Winning Global Nutraceutical Company, British Biologicals, Announces Expansion to North America

2018年09月11日 AM06:26
このエントリーをはてなブックマークに追加


 

EASTVALE, Calif.

British Biologicals, a global nutraceutical company, has announced its plans to expand into the nutrition market in the United States in late 2018. With over 30 years of success in manufacturing and a significant global presence in more than 30 countries, British Biologicals is revered to bring its wide range of nutraceutical science based nutritional supplements that are distinctive and reliable to the North American market.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180910005917/en/

Award Winning Global Nutraceutical Company, British Biologicals, Announces Expansion to North Americ ...

Award Winning Global Nutraceutical Company, British Biologicals, Announces Expansion to North America (Photo: Business Wire)

“Our plans to expand to North America is validation of our consistent endeavors to build innovative nutraceutical products for the wellness of all of society,” stated V. S. Reddy, British Biologicals, Founder. “We strive to raise the bar in accordance with the changing times and expectations of our customers. By expanding to North America, we can continue our dedication to help people lead healthier and more productive lives.”

With over 3,100 employees, British Biologicals boasts five world-class manufacturing facilities located in Bangalore, India, with plans to open another world class facility and headquarters in the United States. The corporation houses accomplished medical experts, nutritionists and dieticians administered by a highly-experienced and innovative team of professionals, who are dedicated to the ideology of excellent human health and well-being. Currently, British Biologicals exports products to South East Asia, the Middle East, East Africa, and the West Indies, and are now rapidly growing in the European and American markets. British Biologicals is the only Indian corporation exporting nutritional supplements to the United Kingdom, and today is recognized as India’s top medical nutrition company.

British Biologicals’ newest 50,000 sq. ft. world-class manufacturing facility will be stationed in Eastvale, California and has an expected completion date for February 2019. The corporation plans to hire additional staff for the new facility.

British Biologicals was founded in 1988 by V. S. Reddy and was recently recognized as “Asia’s Most Admired Brand of 2017-2018” by the Asian Brand & Leadership Conclave. Public consumers across the globe recognize British Biologicals as D-Protin and B-Protin people. For more information on British Biologicals visit http://www.britishbiologicals.com/.

About British Biologicals:

British Biologicals is an Indian Nutraceutical company, founded in 1988 by Mr. V S Reddy. British Biologicals is headquartered at Bangalore and is popularly known as ‘The Protein People’. The company offers wide range of Nutraceutical science-based nutritional supplements that are distinctive, reliable and 100% safe for human consumption. British Biologicals is proud to attain dignified USA quality standards and excellence and currently exports products to South East Asia, the Middle East, East Africa, and the West Indies, and are growing in the European and American markets. With a high-volume production capacity per day, our facility is the largest and the most advanced of its kind in the whole of South East Asia.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180910005917/en/

CONTACT

BN Labs
Kristen Jones, k.jones@bn-labs.com

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • Namaste Receives Health Canada’s First ACMPR Sales-Only License
  • British Biologicals’ USA Leadership Team Equipped for Launch of NEW California Based Operating Facility
  • Alexion Announces Successful Phase 3 PREVENT Study of Soliris® (Eculizumab) in Patients with Neuromyelitis Optica Spectrum Disorder (NMOSD)
  • Seattle Genetics Announces ADCETRIS® (Brentuximab Vedotin) Approval in Japan for Frontline Hodgkin Lymphoma
  • MicuRx Announces Receipt of FDA’s QIDP and Fast Track Designations for Contezolid and Contezolid Acefosamil